Keryx biopharmaceuticals inc (KERX)
CashFlow / Yearly
Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Cash flows from operating activities
Net loss

-163,440

-161,095

-123,145

-111,518

-46,732

-22,721

-28,123

-20,331

10,485

Gain from discontinued operations

-

-

-

-

-

-

246

120

3

Extraordinary gain

-

-

-

-

-

2,639

-

0

-

Loss before extraordinary gain

-

-

-

-

-46,732

-

-

-

-

Loss from continuing operations

-

-

-

-

-

-25,360

-28,369

-20,451

10,482

Adjustments to reconcile net loss to cash flows used in operating activities:
Stock-based compensation expense

18,272

13,989

16,500

26,957

5,953

2,167

2,092

2,473

3,100

Amortization of debt discount

62,965

34,227

11,357

0

-

-

-

-

-

Change in fair value of derivative liability

-225

4,718

1,102

0

-

-

-

-

-

Depreciation and amortization

937

1,005

596

306

54

35

47

-

-

Cash received from landlord

0

-637

-1,276

0

-

-

-

-

-

Amortization of deferred lease incentive

244

244

163

0

-

-

-

-

-

Loss on disposal of fixed assets

-10

-54

-507

0

-

-

-

-

-

Write-down of inventory to net realizable value

3,467

27,968

0

0

-

-

-

-

-

Deferred income taxes

-235

80

90

700

-

-

-

-

-

Changes in operating assets and liabilities:
Depreciation and amortization

-

-

-

-

-

-

-

60

92

Loss on sale of investment securities

-

-

-

-

-

-

-

-82

173

Impairment of investment securities

-

-

-

-

-

-

-

32

68

Other current assets

8,029

340

-1,262

2,860

802

-104

334

-1,321

1,013

Accounts receivable, net

2,910

1,580

2,822

834

-

-

-

-

-

Inventory

-

-

-

7,771

-

-

-

-

-

Security deposits

0

0

-807

0

-

-

-

-

-

Increase in security deposits

-

-

-

-

-

-

51

50

-

Other assets

8,466

11

-355

11

83

-11

21

6

-3

Accrued interest receivable

0

0

-47

48

-

-7

7

-66

41

Inventory

19,496

2,300

29,189

-

-

-

-

-

-

Other current liabilities

28

-238

0

0

-

-

-

-

-

Accounts payable and accrued expenses

24,023

88

-8,478

13,569

6,792

-1,658

3,592

376

388

Accrued compensation and related liabilities

-

-

-

-

497

-70

228

-86

259

Deferred revenue

0

-3,526

3,112

414

-

-

-

-

-18,616

Other liabilities

-146

-36

943

95

2

1

-

-15

-68

Net cash provided by operating activities of discontinued operations

-

-

-

-

-

-

1

-10

3

Net cash used in operating activities

-

-

-

-

-

-24,763

-22,822

-16,208

-5,516

Net cash used in operating activities

-93,489

-86,604

-127,457

-81,001

-34,319

-24,763

-22,823

-16,198

-5,519

Cash flows from investing activities
Purchases of property, plant and equipment

1,257

2,074

2,777

1,489

346

24

57

23

4

Proceeds from sale of available-for-sale long-term securities

-

-

-

-

-

-

-

1,620

5,557

Net cash used in investing activities

-

-

-

-

-

4,188

-4,168

19,045

-9,697

Investment in held-to-maturity short-term securities

0

0

0

49,771

24,403

11,263

9,941

18,366

17,593

Proceeds from maturity of held-to-maturity short-term securities

0

0

11,508

38,263

24,403

15,475

5,830

35,814

2,343

Net cash used in investing activities

-1,257

-2,074

8,731

-12,997

-346

-

-

-

-

Cash flows from financing activities
Proceeds from issuance of common stock, net of commission

75,720

0

118,284

107,532

-

-

30,734

0

18,438

Proceeds from issuance of convertible senior notes

0

0

125,000

0

-

-

-

-

-

Gross proceeds from public offerings

-

-

-

-

80,393

-

-

-

-

Payments for common stock issuance costs

102

0

0

-

5,640

-

-

-

-

Proceeds from exercise of warrants from public offering, net

-

-

-

-

-

-

-

7,305

-

Proceeds from exercise of stock options

1,146

198

1,463

5,054

931

-

3,096

1,884

18

Payments for repurchase of common stock for employee tax withholding

302

0

15

0

-

-

-

-

-

Net cash provided by financing activities

76,462

198

244,732

112,586

75,684

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

33,830

9,189

18,456

Net (decrease) increase in cash and cash equivalents

-18,284

-88,480

126,006

18,588

41,019

-20,575

6,840

12,026

3,243

Reclassification of derivative liability to equity

62,735

51,404

0

0

-

-

-

-

-

Increase of receivable from landlord and deferred lease incentive

0

0

637

0

-

-

-

-

-

Issuance of common stock in connection with contingent equity rights

-

-

-

-

-

-

-

-

1,365

Issuance of warrants to placement agent in public offering

-

-

-

-

-

-

-

-

100